CKD Bio Corp. (KRX:063160)
South Korea
· Delayed Price · Currency is KRW 21,500
+50 (0.23%)
At close: Dec 5, 2025
CKD Bio Revenue
CKD Bio had revenue of 42.34B KRW in the quarter ending September 30, 2023, with 12.64% growth. This brings the company's revenue in the last twelve months to 159.93B, up 3.59% year-over-year. In the year 2022, CKD Bio had annual revenue of 156.04B with 9.70% growth.
Revenue (ttm)
159.93B
Revenue Growth
+3.59%
P/S Ratio
0.74
Revenue / Employee
308.16M
Employees
519
Market Cap
117.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 156.04B | 13.80B | 9.70% |
| Dec 31, 2021 | 142.24B | 17.64B | 14.16% |
| Dec 31, 2020 | 124.60B | -12.58B | -9.17% |
| Dec 31, 2019 | 137.18B | 12.67B | 10.18% |
| Dec 31, 2018 | 124.51B | 10.75B | 9.45% |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
| Dec 31, 2008 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |